Recombinant Anti-ALK Anticorps [ALK1/7008R] (A277986)

Anti-ALK Antibody [ALK1/7008R]

Recombinant rabbit monoclonal [ALK1/7008R] antibody to ALK.

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase of the insulin receptor superfamily. ALK is typically expressed at low levels in regions of the developing central and peripheral nervous system.ALK may be activated in cancer through multiple mechanisms. The most common mechanism is through formation of a fusion protein from chromosomal translocations, as in the case of anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumors. ALK may also be amplified through mutation, as in neuroblastomas. Various solid tumors, such as non-small cell lung carcinoma (NSCLC) and brain cancers were also found to aberrantly express ALK. ALK staining is present within both the nucleus and cytoplasm, and are positive in about 60% of ALCL. ALK protein expression by tumor cells is an independent prognostic factor that predicts a favorable outcome.

IHC-P

IHC-P: 1-2 µg/ml

Human

Recombinant fragment corresponding to the cytoplasmic domain of human ALK.

Rabbit

Monoclonal

ALK1/7008R

IgG

kappa

Protein A/G chromatography.

200 µg/ml

80 kDa (hybrid) / 200 kDa (wild type)

Liquid

Supplied in 10mM Phosphate Buffered Saline with 0.05% BSA and 0.05% Sodium Azide.

Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

This monoclonal antibody is also available in a different formulation without BSA and Sodium Azide - Anti-ALK Antibody [ALK1/7008R] - BSA and Azide free (A278574).

ALK tyrosine kinase receptor, ALK/EML4 fusion gene, included, ALK/NPM1 fusion gene, included, ALK_HUMAN, Anaplastic lymphoma kinase, anaplastic lymphoma kinase (Ki-1), Anaplastic lymphoma kinase Ki1, anaplastic lymphoma receptor tyrosine kinase, CD 246, CD246, CD246 antigen, EC 2.7.10.1, Ki 1, Ki1, mutant anaplastic lymphoma kinase, NBLST 3, NBLST3, Tcrz, TFG/ALK